Physician profile
Michael W Luy
NPI 1720333768
$7,065.75
in general payments reported to CMS, 2019-2025
46 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $984 · 2021: $1,445 · 2022: $556 · 2023: $459 · 2024: $1,144 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.45 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $678.17 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $672.75 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $588.99 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $454.25 | 2019-2025 | Gardasil 9, Capvaxive, Zerbaxa |
| Amgen INC. | $386.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $278.56 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Allergan, INC. | $271.26 | 2019-2021 | |
| Astellas Pharma US INC | $231.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.45 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.15 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $140.72 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $131.46 | 2019-2022 | |
| Gilead Sciences, INC. | $128.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $128.20 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Luy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.